Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time
September 23, 2024 19:10 ET
|
Regen BioPharma, Inc.
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO,...
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
September 14, 2024 07:30 ET
|
Medigene AG
Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
September 09, 2024 16:06 ET
|
Imunon, Inc.
September 18th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline ...
Medigene Announces U.S. FDA Clearance of IND Application for MDG1015, a First-in-Class, Third Generation T Cell Receptor Engineered T Cell (TCR-T) Therapy for Multiple Solid Tumor Indications
September 05, 2024 08:00 ET
|
Medigene AG
Planegg/Martinsried, September 5, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody
September 03, 2024 21:00 ET
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI and SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, Inc. (“EpimAb” or “EpimAb Biotherapeutics”) a clinical stage biopharmaceutical company specializing in the...
Alumis to Participate in Upcoming September Investor Conferences
September 03, 2024 16:29 ET
|
Alumis Inc.
Alumis will be participating in several investor conferences in September
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
August 29, 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, August 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Immunology Market to Reach $204.0 Billion, Globally, by 2033 at 6.3% CAGR: Allied Market Research
August 28, 2024 06:40 ET
|
Allied Analytics LLP
Wilmington, Delaware, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Immunology Market by Product Type (Diagnostic Testing Equipment, Biomarkers and...
Medigene to Present at Upcoming Investor Conferences
August 28, 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, August 28, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Immunology Market Size to Hit USD 254.23 Billion by 2032, Driven by Rising Prevalence of Autoimmune Diseases & Advances in Biologic Therapies | SNS Insider
August 22, 2024 09:00 ET
|
SNS Insider pvt ltd
Pune, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Immunology Market Analysis: “The Immunology Market Size was valued at USD 97.58 Billion in 2023 and is expected to reach USD 254.23 Billion by 2032 and...